Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10418)
All Articles published online
|
Publishing Process of This Article
|
Jan 21, 2020 (publication date) through Nov 8, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 2020; 26(3): 353-365 [PMID: 31988594 DOI: 10.3748/wjg.v26.i3.353] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i3/353.htm |
| Number | Citing Articles |
| 1 |
Seita Kataoka, Michihisa Moriguchi, Shinya Okishio, Aya Takahashi, Keiichiro Okuda, Yuya Seko, Atushi Umemura, Kanji Yamaguchi, Aya Miyagawa-Hayashino, Yoshito Itoh. Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case. Clinical Journal of Gastroenterology 2022; 15(2): 467 doi: 10.1007/s12328-022-01590-z
|
| 2 |
Mar Riveiro-Barciela, Sabela carballal, Álvaro Díaz-González, Miriam Mañosa, Javier Gallgo-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU. Revista Española de Enfermedades Digestivas 2024; doi: 10.17235/reed.2024.10250/2024
|
| 3 |
Takeshi Tanaka, Arata Sakai, Masahiro Tsujimae, Yasutaka Yamada, Takashi Kobayashi, Atsuhiro Masuda, Yuzo Kodama. Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report. World Journal of Gastroenterology 2022; 28(28): 3732-3738 doi: 10.3748/wjg.v28.i28.3732
|
| 4 |
Masaki Takinami, Akira Ono, Takanori Kawabata, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Yoshio Kiyohara, Hirofumi Yasui, Masashi Niwakawa, Toshiaki Takahashi. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Investigational New Drugs 2021; 39(6): 1716 doi: 10.1007/s10637-021-01136-z
|
| 5 |
Tetsushi Azami, Yuichi Takano, Jun Noda, Masataka Yamawaki, Erika Yoshida, Fumitaka Niiya, Naotaka Maruoka, Takafumi Ogawa, Wataru Ichikawa, Masatsugu Nagahama. Anti programmed death-ligand 1 antibody-related cholangitis without bile duct dilation or stenosis. Clinical Journal of Gastroenterology 2022; 15(4): 818 doi: 10.1007/s12328-022-01651-3
|
| 6 |
Kenji Urakabe, Takashi Mizushima, Hironobu Tsukamoto, Yasuaki Fujita, Kenichi Haneda, Yuta Suzuki, Akihisa Minowa, Ryo Ishihara, Yusuke Kito, Kazuko Watanabe, Fumihiro Okumura. Two cases of steroid-resistant nivolumab-induced sclerosing cholangitis. Kanzo 2021; 62(11): 712 doi: 10.2957/kanzo.62.712
|
| 7 |
Joseph William Clinton, Sara Kiparizoska, Soorya Aggarwal, Stephanie Woo, William Davis, James H. Lewis. Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. Drug Safety 2021; 44(11): 1125 doi: 10.1007/s40264-021-01109-4
|
| 8 |
Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama, Mina Komuta, Kenichi Harada, Atsushi Tanaka. Diagnostic guide for immune checkpoint inhibitor‐induced liver injury. Hepatology Research 2024; 54(8): 719 doi: 10.1111/hepr.14078
|
| 9 |
致文 沈. The Advancement in Diagnosis and Therapy of Liver Injury Induced by Immune Checkpoint Inhibitors. Advances in Clinical Medicine 2021; 11(10): 4628 doi: 10.12677/ACM.2021.1110680
|
| 10 |
Nao Takada, Takahiro Fukui, Hidehiro Irie, Yohei Funatsu, Hidefumi Koh. Immune Checkpoint Inhibitor-induced Sclerosing Cholangitis: Three Cases Reported from Our Hospital. Haigan 2024; 64(3): 193 doi: 10.2482/haigan.64.193
|
| 11 |
Zhao Gao, Shikai Wu, Yinmo Yang, Mingxia Sun, Xiaodong Tian, Xuan Jin. Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma. Investigational New Drugs 2023; 41(5): 719 doi: 10.1007/s10637-023-01391-2
|
| 12 |
Shefali Chopra, Samer Gawrieh, Raj Vuppalanchi, Romil Saxena. Role of the Surgical Pathologist in Diagnosis of Drug-induced Liver Injury: Recognizing Specific Patterns of Drug Injury. Advances in Anatomic Pathology 2021; 28(6): 383 doi: 10.1097/PAP.0000000000000307
|
| 13 |
Hao Chi Zhang, Lan Sun Wang, Ethan Miller. Immunotherapy. Advances in Experimental Medicine and Biology 2021; 1342: 339 doi: 10.1007/978-3-030-79308-1_13
|
| 14 |
Ian Liang, Geoffrey Chu, Robert Zielinski. Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy. Case Reports in Oncology 2023; : 188 doi: 10.1159/000530009
|
| 15 |
Ryunosuke Ooi, Kazunori Tobino, Mitsukuni Sakabe, Takafumi Kawabata, Yuri Hiramatsu, Takuto Sueyasu, Kohei Yoshimine. A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis. Respiratory Medicine Case Reports 2020; 31: 101197 doi: 10.1016/j.rmcr.2020.101197
|
| 16 |
Dimitrios C Ziogas, Helen Gogas. Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al. Journal for ImmunoTherapy of Cancer 2021; 9(3): e002391 doi: 10.1136/jitc-2021-002391
|
| 17 |
Lorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, Eric T. Tjwa, Gustav Buescher, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Jérôme Dumortier, Mar Riveiro Barciela, Tom J. G. Gevers, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londoño, Sona Frankova, Thomas Roesner, Vincent Joerg, Constantin Schmidt, Fabian Glaser, Jan P. Sutter, Thorben W. Fründt, Ansgar W. Lohse, Samuel Huber, Johann von Felden, Marcial Sebode, Kornelius Schulze. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease. Frontiers in Immunology 2024; 14 doi: 10.3389/fimmu.2023.1326078
|
| 18 |
Donna Zhuang, David Zhang, Stephen Riordan. Hepatobiliary complications of immune checkpoint inhibitors in cancer. Exploration of Targeted Anti-tumor Therapy 2024; 5(4): 955 doi: 10.37349/etat.2024.00257
|
| 19 |
Babina Gosangi, Lacey McIntosh, Abhishek Keraliya, David Victor Kumar Irugu, Akshay Baheti, Ashish Khandelwal, Richard Thomas, Marta Braschi-Amirfarzan. Imaging features of toxicities associated with immune checkpoint inhibitors. European Journal of Radiology Open 2022; 9: 100434 doi: 10.1016/j.ejro.2022.100434
|
| 20 |
Rohit Agrawal, Grace Guzman, Saman Karimi, Pier Cristoforo Giulianotti, Alfredo Jose Mena Lora, Shikha Jain, Meshaal Khan, Brian R Boulay, Yolande Chen. Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report. World Journal of Clinical Cases 2022; 10(20): 7124-7129 doi: 10.12998/wjcc.v10.i20.7124
|
| 21 |
Shusaku Honma, Satoshi Watanabe, Sanae Nakajima. Pembrolizumab-Related Sclerosing Cholangitis in a Patient With High Microsatellite Instability Gastric Cancer: A Case Report. Cureus 2024; doi: 10.7759/cureus.66425
|
| 22 |
Kefan Chen, Junhao He, Jing Xu, Jie Chen. Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1088741
|
| 23 |
Tess McClure, Wanyuan Cui, Khashayar Asadi, Thomas John, Adam Testro. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up. BMJ Open Gastroenterology 2020; 7(1): e000487 doi: 10.1136/bmjgast-2020-000487
|
| 24 |
Hao Chi Zhang, Lan Sun Wang, Ethan Miller. Managing Immunotherapy Related Organ Toxicities. 2022; : 119 doi: 10.1007/978-3-031-00241-0_7
|
| 25 |
Takayuki Yamamoto, Yukihiro Sugimoto, Ryouta Aoki, Kunihiro Kudou, Hirofumi Nakano, Teruo Nakaya, Mio Nakazato, Masanori Takayama. A Case of Pembrolizumab-related Sclerosing Cholangitis Successfully Treated with Prednisolone. Haigan 2021; 61(7): 951 doi: 10.2482/haigan.61.951
|
| 26 |
Borui Pi, Jin Wang, Yifan Tong, Qiao Yang, Fangfang Lv, Yunsong Yu. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. European Journal of Gastroenterology & Hepatology 2021; 33(1S): e858 doi: 10.1097/MEG.0000000000002280
|
| 27 |
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU. Gastroenterología y Hepatología (English Edition) 2024; 47(4): 401 doi: 10.1016/j.gastre.2023.10.003
|
| 28 |
Yuchen Li, Lori Stewart, Shangguo Tang, Elaine McWhirter. Pembrolizumab-induced immune-related sclerosing cholangitis. BMJ Case Reports 2023; 16(11): e256125 doi: 10.1136/bcr-2023-256125
|
| 29 |
Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama, Mina Komuta, Kenichi Harada, Atsushi Tanaka. Guide for the Diagnosis of Immune Checkpoint Inhibitor-Induced Liver Injury. Kanzo 2024; 65(6): 268 doi: 10.2957/kanzo.65.268
|
| 30 |
Sachiko Matsumoto, Keisuke Watanabe, Nobuaki Kobayashi, Kuniyasu Irie, Shoji Yamanaka, Takeshi Kaneko. Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient. Respirology Case Reports 2020; 8(5) doi: 10.1002/rcr2.560
|
| 31 |
Fernando Bessone, Einar Stefan Bjornsson. Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach. World Journal of Hepatology 2022; 14(7): 1269-1276 doi: 10.4254/wjh.v14.i7.1269
|
| 32 |
Fernando Bessone, Einar S. Björnsson. Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors. Medical Clinics of North America 2023; 107(3): 623 doi: 10.1016/j.mcna.2022.12.008
|
| 33 |
J. McKenzie, E. Sneath, A. Trinh, M. Nolan, L. Spain. Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities. Immuno-Oncology and Technology 2024; 21: 100704 doi: 10.1016/j.iotech.2024.100704
|
| 34 |
Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Jill Brufsky, Laura C Cappelli, Frank B Cortazar, David E Gerber, Lamya Hamad, Eric Hansen, Douglas B Johnson, Mario E Lacouture, Gregory A Masters, Jarushka Naidoo, Michele Nanni, Miguel-Angel Perales, Igor Puzanov, Bianca D Santomasso, Satish P Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A Sosman, Michelle Turner, Marc S Ernstoff. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for ImmunoTherapy of Cancer 2021; 9(6): e002435 doi: 10.1136/jitc-2021-002435
|
| 35 |
Marie-Léa Gauci, Barouyr Baroudjian, Celeste Lebbe, Olivier Roux. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. Journal for ImmunoTherapy of Cancer 2021; 9(3): e002337 doi: 10.1136/jitc-2021-002337
|
| 36 |
Einar S. Björnsson, Raul J. Andrade. Long-term sequelae of drug-induced liver injury. Journal of Hepatology 2022; 76(2): 435 doi: 10.1016/j.jhep.2021.10.011
|
| 37 |
Yuki Yoshikawa, Michio Imamura, Kenji Yamaoka, Yumi Kosaka, Eisuke Murakami, Kei Morio, Hatsue Fujino, Takashi Nakahara, Wataru Okamoto, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Clair Nelson Hayes, Hiroshi Aikata, Kazunori Fujitaka, Kouji Arihiro, Noboru Hattori, Kazuaki Chayama. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. Clinical Journal of Gastroenterology 2021; 14(1): 283 doi: 10.1007/s12328-020-01287-1
|
| 38 |
Brian H. Horwich, Douglas T. Dieterich. Phenotypes of Primary Sclerosing Cholangitis and Differential Diagnosis. Clinics in Liver Disease 2024; 28(1): 143 doi: 10.1016/j.cld.2023.07.006
|
| 39 |
Emanuel Raschi, Milo Gatti, Francesco Gelsomino, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio De Ponti. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Targeted Oncology 2020; 15(4): 449 doi: 10.1007/s11523-020-00738-6
|
| 40 |
Lina Hountondji, Christophe Ferreira De Matos, Fanny Lebossé, Xavier Quantin, Candice Lesage, Pascale Palassin, Valérian Rivet, Stéphanie Faure, Georges-Philippe Pageaux, Éric Assenat, Laurent Alric, Amel Zahhaf, Dominique Larrey, Philine Witkowski Durand Viel, Benjamin Riviere, Selves Janick, Stéphane Dalle, Alexandre Thibault Jacques Maria, Thibaut Comont, Lucy Meunier. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Reports 2023; 5(6): 100719 doi: 10.1016/j.jhepr.2023.100719
|
| 41 |
Akihiro Tsukaguchi, Norihiko Yamaguchi, Hiroyuki Ogawa, Toshiyuki Ikeda. Concurrent Nivolumab-Induced Gastritis and Cholangitis Accompanied by Biliary Tract Hemorrhage in a Patient With Stage IV Lung Adenocarcinoma. Cureus 2023; doi: 10.7759/cureus.46392
|
| 42 |
Takafumi Yamamoto, Kazuyuki Mizuno, Takanori Ito, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Takuya Ishikawa, Akira Kanamori, Satoshi Yasuda, Hidenori Toyoda, Kenji Yokota, Tetsunari Hase, Naoki Nishio, Osamu Maeda, Makoto Ishii, Michihiko Sone, Yuichi Ando, Masashi Akiyama, Masatoshi Ishigami, Hiroki Kawashima. Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis. Investigational New Drugs 2023; 41(3): 512 doi: 10.1007/s10637-023-01366-3
|
| 43 |
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU. Gastroenterología y Hepatología 2024; 47(4): 401 doi: 10.1016/j.gastrohep.2023.10.009
|
| 44 |
Shinji Nabeshima, Masahiro Yamasaki, Naoko Matsumoto, Shintaro Takaki, Yumi Nishi, Kazuma Kawamoto, Masaya Taniwaki, Nobuyuki Ohashi, Noboru Hattori. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report. Cancer Treatment and Research Communications 2021; 26: 100270 doi: 10.1016/j.ctarc.2020.100270
|
| 45 |
Daniel R. Ludwig, Mark A. Anderson, Malak Itani, Kedar G. Sharbidre, Neeraj Lalwani, Raj M. Paspulati. Secondary sclerosing cholangitis: mimics of primary sclerosing cholangitis. Abdominal Radiology 2022; 48(1): 151 doi: 10.1007/s00261-022-03551-z
|
| 46 |
Joshua Newington, Daniel Patterson, Pilar Sanchez. Delayed onset autoimmune cholangitis in a patient treated with pembrolizumab. BJR|Case Reports 2024; 10(6) doi: 10.1093/bjrcr/uaae040
|
| 47 |
Johanna Winter, Max M. Lenders, Maximilian Gassenmaier, Andrea Forschner, Ulrike Leiter, Benjamin Weide, Mette-Triin Purde, Lukas Flatz, Antonio Cozzio, Martin Röcken, Claus Garbe, Thomas K. Eigentler, Nikolaus B. Wagner. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancer Immunology, Immunotherapy 2021; 70(4): 1089 doi: 10.1007/s00262-020-02768-5
|
| 48 |
Yoshiya Takeda, Osamu Inatomi, Shuhei Shintani, Takehide Fujimoto, Atsushi Nishida, Hiromu Kutsumi, Akira Andoh. Clinical response in the haustra-like folds observed during peroral cholangioscopy following steroid therapy for immune checkpoint inhibitor-induced cholangitis. Endoscopy 2022; 54(S 02): E1020 doi: 10.1055/a-1899-8619
|
| 49 |
Zheqing Liu, Xiaojing Du, Meiling Deng, Yuanyuan Chen, Shaoxiong Wu. Successful replacement for recurrent nasopharyngeal carcinoma with cholecystitis induced by PD-1 antibody: a case report. Immunotherapy 2024; 16(14-15): 949 doi: 10.1080/1750743X.2024.2382670
|
| 50 |
Robert J. Fontana, Yi-Ju Li, Vincent Chen, David Kleiner, Andrew Stolz, Joe Odin, Raj Vuppalanchi, Jiezhun Gu, Lily Dara, Huiman Barnhart. Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors. Hepatology Communications 2024; 8(9) doi: 10.1097/HC9.0000000000000518
|
| 51 |
Sam Talbot, Vivienne MacLaren, Heather Lafferty. Sclerosing cholangitis in a patient treated with nivolumab. BMJ Case Reports 2021; 14(5): e241700 doi: 10.1136/bcr-2021-241700
|
| 52 |
Jean-Yves Scoazec. Drug-induced bile duct injury: new agents, new mechanisms. Current Opinion in Gastroenterology 2022; 38(2): 83 doi: 10.1097/MOG.0000000000000813
|
| 53 |
Lucy Meunier, Lina Hountondji, Hélène Jantzem, Jean Luc Faillie, Alexandre Maria, Pascale Palassin, Stéphanie Faure, Philine Witkowski-Durand-Viel, Xavier Quantin, Georges Philippe Pageaux. Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data. Clinical Gastroenterology and Hepatology 2024; 22(7): 1542 doi: 10.1016/j.cgh.2023.12.008
|
| 54 |
Mauro Cataldi, Federica Manco, Giovanni Tarantino. Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. International Journal of Molecular Sciences 2021; 22(23): 12947 doi: 10.3390/ijms222312947
|
| 55 |
Leilei Ai, Jian Chen, Hao Yan, Qiaojun He, Peihua Luo, Zhifei Xu, Xiaochun Yang. <p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p>. Drug Design, Development and Therapy 2020; : 3625 doi: 10.2147/DDDT.S267433
|
| 56 |
An-Tian Chen, Yue-Quan Shi, Bei Tan, Liang Zhu, Ya-Ping Luo, Wei Zhong, Meng-Zhao Wang, Yan Xu. Case Report: A Programmed Cell Death-1 Inhibitor-Related Abdominal Fibroinflammatory Reaction Affecting Multiple Organs in A Non-Small-Cell Lung Cancer Patient. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.874932
|
| 57 |
Takafumi Yamamoto, Takanori Ito, Kazuyuki Mizuno, Yokoyama Shinya, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Hiroki Kawashima, Toshinori Matsui, Tetsunari Hase, Naozumi Hashimoto, Masatoshi Ishigami. A case of antiprogrammed death‐ligand 1 antibody‐induced multisystem immune‐related adverse events with pancreatitis and steroid‐resistant sclerosing cholangitis. Journal of Digestive Diseases 2022; 23(7): 404 doi: 10.1111/1751-2980.13122
|
| 58 |
Kentaro Sato, Manabu Hayashi, Kazumichi Abe, Masashi Fujita, Atsushi Takahashi, Hiromasa Ohira. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report. Clinical Journal of Gastroenterology 2020; 13(6): 1310 doi: 10.1007/s12328-020-01178-5
|
| 59 |
Takanori Ito, Kazuyuki Mizuno, Takafumi Yamamoto, Tsukasa Yasuda, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Masayo Hama, Tomomi Kataoka, Tomoya Shimokata, Yuichi Ando, Hiroki Kawashima. Outcomes of immune checkpoint inhibitor‐induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team. Hepatology Research 2024; 54(11): 1060 doi: 10.1111/hepr.14043
|
| 60 |
Andrew Kynaston, Ken Liu, Alex Davis, Steven Kao, Catriona McKenzie. A case of steroid responsive nivolumab induced cholangitis. Pathology 2022; 54(6): 820 doi: 10.1016/j.pathol.2021.11.009
|
| 61 |
Takafumi Yamano, Masamitsu Hamakawa, Yoko Akaike, Tadashi Ishida. A case report of immune checkpoint inhibitor‐related myositis and cholangitis induced by pembrolizumab. Clinical Case Reports 2024; 12(7) doi: 10.1002/ccr3.9153
|
| 62 |
Kohei Okamoto, Susumu Hijioka, Yoshikuni Nagashio, Mao Okada, Akihiro Ohba, Yuta Maruki, Shunsuke Kondo, Chigusa Morizane, Hideki Ueno, Takuji Okusaka. Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments. Japanese Journal of Clinical Oncology 2024; 54(8): 887 doi: 10.1093/jjco/hyae060
|